Tempus AI TEM
United StatesHealthcare · Health Information ServicesUSD
70.06 USD (−0.4%)
18 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Tempus AI is a healthcare technology company that uses artificial intelligence and clinical and genomic data to deliver precision diagnostics and tools to physicians and patients, generating revenue from the sale of its services and data products.
Key points
from its scores- ✓Strong growth8.4
- ✕Unfavourable risk and backdrop0.3
- ✕Little or no dividend0.5
- ✕Demanding valuation0.8
AI analysis
bottom line, main risk, context and newsHigh-growth company with a solid balance sheet but no profitability in sight: only suitable for high-risk profiles that believe in its long-term thesis; the rest should wait until it demonstrates a credible path to profit.
Tempus AI is growing strongly (revenue +21.6%) and has a healthy balance sheet with net cash (Net Debt/EBITDA of -3.25), but it is burning cash intensely: operating margin of -20.1%, ROE of -67.4% and negative FCF yield. Valuation is extremely demanding (score 0.8) and momentum is very negative (-38.8% over 12 months), reflecting market skepticism about its path to profitability.
The main risk is structural cash burn: with an operating margin of -20.1% and an ROE of -67.4%, the company depends on continuous external financing to sustain its growth, and any slowdown in capital raising or platform adoption could compromise its viability.
Context and risks
No recent news and no material exposure to current macro factors (rates, oil, tariffs). The healthcare software and data business does not depend on commodities or shipping routes, and its net cash balance sheet insulates it from the rise in rates. The main risk is operational: very negative margins and cash burn in a growth-stage business.
Is Tempus AI stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 159% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 28.5 | 4.1 | +593% |
| Price / sales | 8.9 | 3.4 | +159% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 70.06 USD, −0.4% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.0 (sector 5.5), Growth 8.4 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −8,695.9
- EV / EBITDA
- −70.4
- Price / book
- 28.5
- Price / sales
- 8.9
- Market cap
- 12.7B USD
- Enterprise value
- 13.6B USD
Profitability
- ROE
- −67.4%
- ROA
- −8.5%
- ROIC (approx.)
- −15.2%
- Gross margin
- 64.0%
- Operating margin
- −20.1%
- Net margin
- −17.8%
- Free cash flow
- −93.5M USD
- FCF yield
- −0.7%
Solvency
- Total debt
- 1.4B USD
- Net debt
- 628.2M USD
- Cash
- 816.0M USD
- EBITDA
- −193.4M USD
- Net debt / EBITDA
- −3.25
- Debt / equity
- 324.58
- Current ratio
- 3.30
- Quick ratio
- 3.01
Growth
- Revenue growth
- +21.6%
- EPS (TTM)
- −1.44 USD
- EPS (forward)
- −0.01 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 3.54
- Analyst consensus
- Buy (18)
- Target price
- 70.06 USD
- 52-week range
- 40.77 – 104.32
Recent news
All TEM news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Tempus AI
Is Tempus AI stock cheap or expensive?
On Price / sales, it trades 159% above the Healthcare median. Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 70.06 USD, −0.4% versus the price. This is not investment advice.
What score does Tempus AI get on MeridIAn Screener?
It scores 3.1 out of 10, rank 2,081 of 2,130 (better than 2% of the companies analysed). Its strongest category is Growth (8.4) and its weakest, Risk & Context (0.3). Analysis of 08/10/2026.
How much is Tempus AI worth on the stock market?
Its market capitalisation is 12.7B USD and its enterprise value, debt included, is 13.6B USD.
How much debt does Tempus AI have?
Its net debt (debt minus cash) is 628.2M USD.
Does Tempus AI pay a dividend?
It pays no dividend, or almost none.
How has Tempus AI stock performed over the last year?
It has fallen 27.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 40.77 and 104.32 USD. Past performance does not guarantee future results.
What do analysts think of Tempus AI?
18 analysts cover it; their average recommendation is “Buy” and their average target is 70.06 USD (−0.4% versus the price). It is an estimate, not market data.